EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

Inclusion Criteria:

1. Males or females who are at least 18 years of age at the time of informed consent

2. Willing and able to provide signed informed consent (participant or legallyauthorized representative) prior to any study-related procedures and to comply withall study visits and cooperate with all examinations

3. Diagnosis of diabetes mellitus (Type 1 or Type 2), with history of diabetic macularedema (DME) < = years duration prior to Screening Visit 1

4. Currently monitored hemoglobin A1c values ≤ 10.0 while under the care of a qualifiedmedical provider for diabetes mellitus management, unless provider allows valuevariance Inclusion criteria for the study eye (all of the below criteria must be met in thesame eye):

5. Early Treatment Diabetic Retinopathy Study BCVA score ≤ 70 letters (Snellenequivalent 20/40 or worse) and ≥ 20 letters (Snellen equivalent 20/400) in at least 1 eye

Exclusion Criteria:

1. Previous or current diagnosis of any form of glaucoma (defined as cup-to-disc ratio > 0.7) or ocular hypertension (documented intraocular pressure (IOP) > 21 mm Hgwithout glaucomatous disc damage) requiring medical or surgical intervention

2. History of steroid-induced IOP elevation > 25 mm Hg

3. Presence of active proliferative diabetic retinopathy, defined as activeneovascularization of disc (NVD), neovascularization elsewhere (NVE),neovascularization of iris (NVI), neovascularization of angle (NVA), or vitreoushemorrhage in the setting of active NVD or NVE